US 12,201,671 B2
Polypeptides for treatment of cancer
Jean-Francois Jasmin, Philadelphia, PA (US); Shannon Chilewski, Philadelphia, PA (US); and Isabelle Mercier, Philadelphia, PA (US)
Assigned to Saint Joseph's University, Philadelphia, PA (US)
Appl. No. 17/607,100
Filed by Saint Joseph's University, Philadelphia, PA (US)
PCT Filed May 13, 2020, PCT No. PCT/US2020/032638
§ 371(c)(1), (2) Date Oct. 28, 2021,
PCT Pub. No. WO2020/232095, PCT Pub. Date Nov. 19, 2020.
Claims priority of provisional application 62/848,980, filed on May 16, 2019.
Prior Publication US 2022/0184177 A1, Jun. 16, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 14 Claims
 
1. A method of treating or ameliorating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a polypeptide consisting essentially of:
(a) amino acid residues 356-400 of co-activator of activator protein-1 and estrogen receptor (CAPER) isoform HCC1.3 (SEQ ID NO. 1);
or
(b) amino acid residues 356-400 of CAPER isoform HCC1.4 (SEQ ID NO. 2).